<DOC>
	<DOCNO>NCT01757470</DOCNO>
	<brief_summary>Effectiveness risk minimisation intervention vandetanib Canada</brief_summary>
	<brief_title>Vandetanib Risk Minimisation Effectiveness</brief_title>
	<detailed_description>As part new drug approval process Canada , AstraZeneca commit Health Canada conduct Drug Utilization Study among patient recently treat CAPRELSA ( vandetanib ) Knowledge Understanding Survey among prescribe physician determine whether product monograph , communication plan , educational material develop AstraZeneca Canada vandetanib adequate provide knowledge potential risk associate product , medication take concomitantly vandetanib manage adequately .</detailed_description>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>N/A ( patient take Caprelsa prescribers contact participation ) . N/A</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>effectiveness risk mitigation ,</keyword>
	<keyword>knowledge understand survey ,</keyword>
	<keyword>drug utilisation study ,</keyword>
	<keyword>post marketing commitment</keyword>
</DOC>